Papillary renal cell carcinoma: current progress and future directions.

Area of Science:

• Oncology
• Genitourinary Cancers

Background:

• Papillary renal cell carcinoma (pRCC) is the second most common kidney cancer subtype.
• pRCC has a distinct molecular profile compared to clear-cell carcinoma and lacks VHL gene mutations.
• This cancer subtype shows limited response to contemporary kidney cancer therapies.

Purpose of the Study:

• To outline the heredity and biology of the two main pRCC variants.
• To discuss emerging therapeutic targets for pRCC treatment.
• To review preclinical data and clinical trials for novel pRCC therapies.

Main Methods:

• Review of scientific literature on pRCC heredity and biology.
• Analysis of preclinical data on MET and EGFR pathway inhibition.
• Summary of completed and ongoing clinical trials for pRCC.

Main Results:

• pRCC exhibits unique genetic and molecular characteristics.
• Inhibition of mesenchymal epithelial transition (MET) and epidermal growth factor receptor (EGFR) pathways are promising therapeutic strategies.
• Combination therapy with MET and EGFR inhibitors shows potential based on preclinical data.

Conclusions:

• Targeting MET and EGFR pathways offers new therapeutic avenues for pRCC.
• Ongoing clinical trials are crucial for expanding treatment options for pRCC patients.
• Further research into pRCC biology is essential for developing effective treatments.